Basilea Pharmaceutica AG (SWX: BSLN)
Switzerland
· Delayed Price · Currency is CHF 45.40
-0.15 (-0.33%)
Sep 4, 2024, 5:30 PM CET
Basilea Pharmaceutica AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 52.54 | 33.56 | 17.99 | 13.82 | 4.04 | 2.56 | Upgrade
|
| Revenue Growth (YoY) | 157.23% | 86.61% | 30.19% | 242.04% | 57.71% | 258.18% | Upgrade
|
| Cost of Revenue | 6.43 | 5.09 | 3.62 | 3.75 | 2.37 | 2.22 | Upgrade
|
| Gross Profit | 46.11 | 28.47 | 14.37 | 10.07 | 1.67 | 0.34 | Upgrade
|
| Selling, General & Admin | 44.16 | 31.78 | 19.38 | 14.05 | 9.66 | 7.27 | Upgrade
|
| Research & Development | 6.87 | 5.6 | 5.19 | 4.99 | 4.01 | 4.74 | Upgrade
|
| Other Operating Expenses | -0.23 | -0.25 | -0.36 | -0.21 | -0.2 | -0.28 | Upgrade
|
| Operating Expenses | 50.8 | 37.13 | 24.22 | 18.83 | 13.46 | 11.73 | Upgrade
|
| Operating Income | -4.69 | -8.66 | -9.85 | -8.77 | -11.79 | -11.39 | Upgrade
|
| Interest Expense | - | - | - | -1.38 | -0.85 | -0.65 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.6 | 0.43 | 0.22 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.29 | -2.3 | -0.79 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.14 | 2.15 | -1.75 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -2.84 | -8.81 | -12.39 | -9.55 | -12.2 | -11.82 | Upgrade
|
| Impairment of Goodwill | -4.37 | -4.37 | -3.6 | - | - | - | Upgrade
|
| Asset Writedown | -0.17 | -0.17 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.11 | - | Upgrade
|
| Pretax Income | -7.37 | -13.35 | -15.99 | -9.55 | -12.09 | -11.82 | Upgrade
|
| Income Tax Expense | 1.52 | 0.38 | -1.4 | -2.01 | -0.57 | -0.57 | Upgrade
|
| Net Income | -8.89 | -13.73 | -14.6 | -7.54 | -11.52 | -11.25 | Upgrade
|
| Net Income to Common | -8.89 | -13.73 | -14.6 | -7.54 | -11.52 | -11.25 | Upgrade
|
| Shares Outstanding (Basic) | 29 | 37 | 34 | 33 | 24 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 37 | 34 | 33 | 24 | 16 | Upgrade
|
| Shares Change (YoY) | -17.17% | 7.91% | 3.37% | 34.86% | 53.69% | 81.36% | Upgrade
|
| EPS (Basic) | -0.31 | -0.38 | -0.43 | -0.23 | -0.47 | -0.71 | Upgrade
|
| EPS (Diluted) | -0.31 | -0.38 | -0.43 | -0.23 | -0.47 | -0.71 | Upgrade
|
| Free Cash Flow | -3.25 | -9.16 | -7.74 | -5.76 | -9.3 | -10.93 | Upgrade
|
| Free Cash Flow Per Share | -0.11 | -0.25 | -0.23 | -0.18 | -0.38 | -0.69 | Upgrade
|
| Gross Margin | 87.77% | 84.83% | 79.89% | 72.86% | 41.37% | 13.32% | Upgrade
|
| Operating Margin | -8.92% | -25.79% | -54.74% | -63.46% | -291.83% | -444.83% | Upgrade
|
| Profit Margin | -16.91% | -40.90% | -81.15% | -54.59% | -285.22% | -439.36% | Upgrade
|
| Free Cash Flow Margin | -6.18% | -27.29% | -43.04% | -41.72% | -230.26% | -426.94% | Upgrade
|
| EBITDA | -3.05 | -6.56 | -7.5 | -6.34 | -9.48 | -8.97 | Upgrade
|
| EBITDA Margin | -5.80% | -19.55% | -41.70% | -45.90% | -234.81% | - | Upgrade
|
| D&A For EBITDA | 1.64 | 2.1 | 2.35 | 2.43 | 2.3 | 2.42 | Upgrade
|
| EBIT | -4.69 | -8.66 | -9.85 | -8.77 | -11.79 | -11.39 | Upgrade
|
| EBIT Margin | -8.92% | -25.79% | -54.74% | -63.46% | -291.83% | - | Upgrade
|
| Revenue as Reported | 52.54 | 33.56 | 17.99 | 13.82 | 4.04 | 2.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.